BACKGROUND AND PURPOSE: Heme oxygenase-1 (HO-1) is an inducible Phase 2 enzyme that degrades toxic heme; its role in cerebral ischemia is not fully understood. We hypothesize that chemically induced HO-1 upregulation with the novel triterpenoid CDDO-Im (2-cyano-3,12 dioxooleana-1,9 dien-28-oyl imidazoline), a robust inducer of Phase 2 genes, protects neurons against ischemic injury. METHODS: Using 3 different models of ischemia, including oxygen-glucose deprivation in neuronal cultures, global ischemia in rats, and focal ischemia in mice, we determined (1) whether CDDO-Im induces HO-1 expression and protects against ischemic injury; and (2) whether HO-1 inhibition disrupts the neuroprotective effect of CDDO-Im. RESULTS: CDDO-Im treatment (50-300 nmol/L) resulted in 8-fold HO-1 upregulation in cultured neurons and protected against oxygen-glucose deprivation. The protection was abolished when the cultures were transfected with nuclear factor (erythroid-derived 2) like-2-shRNA or coincubated with tin protoporphyrin IX, a specific HO-1 inhibitor. In the rat model of global ischemia, intracerebroventricular infusion of CDDO-Im (0.5-1.5 μg) augmented HO-1 expression in hippocampal neurons and resulted in significant increases in CA1 neuronal survival after global ischemia. To further strengthen the clinical relevance of the CDDO-Im treatment, we tested its effects in the mouse model of temporary focal ischemia (60 minutes). Postischemic intraperitoneal injection of CDDO-Im (10-100 μg) enhanced HO-1 expression and significantly reduced neurological dysfunction and infarct volume. Intracerebroventricular infusion of tin protoporphyrin IX reduced the neuroprotective effect of CDDO-Im against global and focal ischemia. CONCLUSIONS: CDDO-Im confers neuroprotection against ischemic injury by upregulating HO-1, suggesting that enhance of HO-1 expression may be a legitimate strategy for therapeutic intervention of stroke.
BACKGROUND AND PURPOSE:Heme oxygenase-1 (HO-1) is an inducible Phase 2 enzyme that degrades toxic heme; its role in cerebral ischemia is not fully understood. We hypothesize that chemically induced HO-1 upregulation with the novel triterpenoidCDDO-Im (2-cyano-3,12 dioxooleana-1,9 dien-28-oyl imidazoline), a robust inducer of Phase 2 genes, protects neurons against ischemic injury. METHODS: Using 3 different models of ischemia, including oxygen-glucose deprivation in neuronal cultures, global ischemia in rats, and focal ischemia in mice, we determined (1) whether CDDO-Im induces HO-1 expression and protects against ischemic injury; and (2) whether HO-1 inhibition disrupts the neuroprotective effect of CDDO-Im. RESULTS:CDDO-Im treatment (50-300 nmol/L) resulted in 8-fold HO-1 upregulation in cultured neurons and protected against oxygen-glucose deprivation. The protection was abolished when the cultures were transfected with nuclear factor (erythroid-derived 2) like-2-shRNA or coincubated with tin protoporphyrin IX, a specific HO-1 inhibitor. In the rat model of global ischemia, intracerebroventricular infusion of CDDO-Im (0.5-1.5 μg) augmented HO-1 expression in hippocampal neurons and resulted in significant increases in CA1 neuronal survival after global ischemia. To further strengthen the clinical relevance of the CDDO-Im treatment, we tested its effects in the mouse model of temporary focal ischemia (60 minutes). Postischemic intraperitoneal injection of CDDO-Im (10-100 μg) enhanced HO-1 expression and significantly reduced neurological dysfunction and infarct volume. Intracerebroventricular infusion of tin protoporphyrin IX reduced the neuroprotective effect of CDDO-Im against global and focal ischemia. CONCLUSIONS:CDDO-Im confers neuroprotection against ischemic injury by upregulating HO-1, suggesting that enhance of HO-1 expression may be a legitimate strategy for therapeutic intervention of stroke.
Authors: Tadashi Honda; Yukiko Honda; Frank G Favaloro; Gordon W Gribble; Nanjoo Suh; Andrew E Place; Mara H Rendi; Michael B Sporn Journal: Bioorg Med Chem Lett Date: 2002-04-08 Impact factor: 2.823
Authors: Karen Liby; Thomas Hock; Mark M Yore; Nanjoo Suh; Andrew E Place; Renee Risingsong; Charlotte R Williams; Darlene B Royce; Tadashi Honda; Yukiko Honda; Gordon W Gribble; Nathalie Hill-Kapturczak; Anupam Agarwal; Michael B Sporn Journal: Cancer Res Date: 2005-06-01 Impact factor: 12.701
Authors: S Doré; K Sampei; S Goto; N J Alkayed; D Guastella; S Blackshaw; M Gallagher; R J Traystman; P D Hurn; R C Koehler; S H Snyder Journal: Mol Med Date: 1999-10 Impact factor: 6.354
Authors: Andrew E Place; Nanjoo Suh; Charlotte R Williams; Renee Risingsong; Tadashi Honda; Yukiko Honda; Gordon W Gribble; Lisa M Leesnitzer; Julie B Stimmel; Timothy M Willson; Evan Rosen; Michael B Sporn Journal: Clin Cancer Res Date: 2003-07 Impact factor: 12.531
Authors: R Anne Stetler; Yanqin Gao; Rehana K Leak; Zhongfang Weng; Yejie Shi; Lili Zhang; Hongjian Pu; Feng Zhang; Xiaoming Hu; Sulaiman Hassan; Carolyn Ferguson; Gregg E Homanics; Guodong Cao; Michael V L Bennett; Jun Chen Journal: Proc Natl Acad Sci U S A Date: 2016-06-06 Impact factor: 11.205
Authors: Lei Liu; Mary K Vollmer; Abdullah S Ahmad; Victoria M Fernandez; Hocheol Kim; Sylvain Doré Journal: Free Radic Biol Med Date: 2018-11-17 Impact factor: 7.376